80
L. Sobotta et al. / Journal of Inorganic Biochemistry 155 (2016) 76–81
were obtained on a “Stuart” Bibby apparatus and were not corrected.
Dry flash column chromatography was carried out on Merck silica gel
60, particle size 40–63 μm and Fluka silica gel 90 C18 — reversed
phase. Size-exclusion chromatography was performed on Sephadex
G-25. Thin layer chromatography (TLC) was performed on silica gel
Merck Kieselgel 60 F 254 plates and DC Kieselgel 60 RP-18 F254 and vi-
sualized with UV illumination (λmax 254 or 365 nm). Mass spectrometry
experiments (ES, MALDI TOF) and elemental analyses were carried out
at the Advanced Chemical Equipment and Instrumentation Facility at
the Faculty of Chemistry, Adam Mickiewicz University in Poznan. The
UV–visible (UV–vis) spectra were recorded on Hitachi UV/VIS U-1900
and Shimadzu UV-160A spectrometers; λmax [nm] (log ε). 1D and 2D
NMR experiments were carried out using a Bruker 400 spectrometer.
Chemical shifts (δ) are quoted in parts per million (ppm) and refer to
a residual solvent peak. Coupling constants (J) are quoted in Hertz
(Hz) to the nearest 0.5 Hz. The abbreviations s, t, h and q refer to singlet,
triplet, hidden and quartet, respectively. 1H and 13C signals were
assigned using 1H–1H COSY, HSQC and HMBC experiments. Analytical
HPLC was performed on an Agilent 1200 Series instrument.
4.2.3. [1,4,8,11,15,18,22,25-octakis(1,4,7-trioxanonyl)phthalocyanine]
cobalt(II) (5b)
A rapidly stirred mixture of phthalocyanine 4 (105 mg 0.07 mmol)
and CoCl2∙6H2O (79 mg 0.33 mmol) in 20 mL of DMF were heated at
70 °C for 24 h. After being allowed to cool to room temperature, the re-
action mixture was filtered and evaporated to dryness under reduced
pressure with toluene (60 mL). Column chromatography (CH2Cl2:
CH3OH 15:1, EtOAc, CH2Cl2:CH3OH 4:1) and size-exclusion chromatog-
raphy (Sephadex G-25, methanol) were performed to give dark brown
solid 5b (56 mg, 53% yield). M.p. N 40 °C (mesophase behaviour).
Rf (CH2Cl2: MeOH 15:1) 0.18. UV–vis (CH2Cl2) λmax [nm] (log ε) 727
(4.86), 655 (4.30), 374 (4.33), 321 (4.57). MS (MALDI-TOF) [m/z]
[M + H]+ 1629.3. IR ν [cm−1] 1115, 1214, 1268, 1499, 1601, 2869.
HPLC (Supplementary data) purity 95.81–100.00%.
4.2.4. [1,4,8,11,15,18,22,25-octakis(1,4,7-trioxanonyl)phthalocyanine]
cooper(II) (5c)
A rapidly stirred mixture of phthalocyanine 4 (128 mg 0.08 mmol)
and CuCl2 (57 mg 0.06 mmol) in DMF (20 mL) were heated at 70 °C
for 24 h. After being allowed to cool to room temperature, the reaction
mixture was filtered and evaporated to dryness under reduced pressure
with toluene (60 mL). Column chromatography (CH2Cl2:CH3OH 20:1,
EtOAc, CH2Cl2:CH3OH 15:1) was performed to give dark green solid 5c
(19 mg, 15% yield). M.p. N 50 °C. Rf (CH2Cl2: CH3OH 15:1) 0.16. UV–vis
(CH2Cl2) λmax [nm] (log ε) 740 (5.17), 662 (4.57), 438 (4.07) 326
(4.75). MS (MALDI-TOF) [m/z] [M + H]+ 1633.3. IR ν [cm−1] 1114,
1267, 1501, 1601, 2867; HPLC (Supplementary data) purity 98.38–
100.00%.
4.2. Synthesis
Known compounds, 2,3-dicyanohydroquinone 1, 3,6-bis(1,4,7-
trioxanonyl)-1,2-benzenedicarbonitrile 2, [1,4,8,11,15,18,22,25-
octakis(1,4,7-trioxanonyl)phthalocyanine]magnesium(II) 3, and
[1,4,8,11,15,18,22,25-octakis(1,4,7-trioxanonyl)phthalocyanine]zinc(II)
6 were synthesized following previously published procedures [19].
4.2.1. 1,4,8,11,15,18,22,25-octakis(1,4,7-trioxanonyl)phthalocyanine (4)
Suspension of [1,4,8,11,15,18,22,25-octakis(1,4,7-trioxanonyl)
phthalocyanine]magnesium(II) (3) (100 mg, 0.06 mmol) was rapidly
mixed in trifluoroacetic acid (25 mL) for 3 h. Next, reaction contents
were poured into water and ice mixture (200 mL) and neutralized
with concentrated solution of sodium bicarbonate. Resulting solution
was extracted with CH2Cl2 (200 mL) and combined organic layers
were after drying with anhydrous MgSO4 were evaporated to dryness.
Column chromatography (CH2Cl2:CH3OH 15:1) was performed to give
dark green solid 4 (34 mg, 33% yield). M.p. N 50 °C (mesophase behav-
iour). Rf (THF:CH3OH 15:1) 0.65. UV–vis (CH2Cl2): λmax [nm] (log ε):
757 (5.10), 670 (4.54), 396 (4.32), 333 (4.69). MS (MALDI-TOF): m/z
[M + H]+ 1572.7. 1H NMR (400 MHz, pyridine-d5) δ: 8.02 (s, 8 H),
5.35 (t, 3J = 4.5 Hz, 16 H), 4.38 (t, 3J = 4.5 Hz, 16 H), 3.93 (t, 3J =
5.0 Hz, 16 H), 3.65 (t, 3J = 5.0 Hz, 16 H), 3.41 (q, 3J = 7.0 Hz, 16 H),
1.08 (t, 3J = 7.0 Hz, 24 H), 0.07 (s, 2 H). 13C NMR (101 MHz, pyridine-
d5) δ: 151.3, 148.5h (present only as a cross-peak in HMBC), 126.3,
120.1, 71.4, 70.1, 69.5, 69.2, 65.3, 14.3. HPLC (Supplementary data)
purity 95.10–96.49%.
4.3. Photostability
The photostability of the investigated compounds was tested both
under aerobic conditions and with limited access to air. A high pressure
xenon lamp and filter cutting-off wavelengths below 450 nm were
applied. Experiments have been performed according to the method
previously described [34].
4.4. Singlet oxygen generation
The quantum yield of singlet oxygen generation of Pcs was assessed
using 1,3-diphenylisobenzofuran (DPBF, Aldrich). DPBF as a chemical
quencher of singlet oxygen. Pc and DPBF solution was irradiated at a
wavelength corresponding to the Q band of the tested macrocycle.
The experimental procedure has been previously described in details
[18,19,24,25,31,34].
4.5. Anti-proliferative assays
4.2.2. [1,4,8,11,15,18,22,25-octakis(1,4,7-trioxanonyl)phthalocyanine]
manganese(III) chloride (5a)
The cytostatic activity of the tested compounds on human CD4+
T-lymphocyte (CEM), human cervix carcinoma (HeLa) and human
melanoma SK-MEL-5 cells was evaluated as follows: an appropriate
number of tumour cells were suspended in RPMI-1640 growth
medium and were seeded in 200 μl-wells of 96-well microtiter
plates, in the presence (or absence for purposes of control) of vari-
able concentrations of the test compounds. The cell cultures were ir-
radiated with red light at 735 nm for 30 min with a light intensity of
4.5 mW/cm2 (light dose 8.1 J/cm2) (or not irradiated (control)) be-
fore incubation at 37 °C in a humidified CO2-controlled atmosphere
(day 0). Recorded on day 1 and day 2, the irradiated tumour cell
cultures were exposed again to red light irradiation at 735 nm for
30 min, after which the cultures continued to be incubated at 37 °C.
On day 3 (CEM) or day 4 (HeLa, SK-MEL-5), the number of cells
were counted on a Coulter counter. The IC50 value was defined as
the compound concentration required to inhibit tumour cell prolif-
eration by 50%.
A rapidly stirred mixture of phthalocyanine 4 (95 mg 0.06 mmol) and
MnCl2∙4H2O (57 mg 0.06 mmol) in 20 mL of DMF were heated at 70 °C for
24 h. After being allowed to cool to room temperature, the reaction mix-
ture was filtered and evaporated to dryness under reduced pressure with
toluene (60 mL). Dry residue was dissolved in CH2Cl2 (30 mL) and rapidly
mixed with 30 mL of concentrated solution of sodium chloride for 30 min.
Next, organic layer was separated, washed with water (60 mL) and dried
with anhydrous MgSO4. Organic solvent was evaporated under reduced
pressure and dry residue was subjected to column chromatography
(CH2Cl2:CH3OH 15:1, EtOAc, CH2Cl2:CH3OH 15:1) to give dark brown
solid 5a (66 mg, 69% yield). M.p. N 80 °C (mesophase behaviour). Rf
(CH2Cl2:CH3OH 15:1) 0.08. UV–vis (CH2Cl2) λmax [nm] (log ε) 811
(4.96), 729 (4.34), 556 (4.18), 345 (4.53). MS (MALDI-TOF) [m/z] M+
1658.09, [M-Cl]+ 1624.32. IR ν [cm−1] 1070, 1213, 1309, 1503, 2866;
HPLC (Supplementary data) purity 98.56–99.93%.